Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease - Systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Mo, Jin A ^a,b   Lim, Ju Hee ^a   Sul, Ah Ram ^a   Lee, Min ^a   Youn, Young Chul ^c   Kim, Hee Jin ^d  

^a National Evidence Based Healthcare Collaborating Agency   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; KOREA; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; CASE CONTROL STUDY; CEREBROSPINAL FLUID; MILD COGNITIVE IMPAIRMENT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS;

EID: 84923339368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116802     Document Type: Review

References (50)

1. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, et al. (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76: 280-286. doi: 10.1212/WNL.0b013e318207b1b9 PMID: 21178097
2. Golde TE, Schneider LS, Koo EH (2011) Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69: 203-213. doi: 10.1016/j.neuron.2011.01.002 PMID: 21262461
3. Cummings JL (2011) Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 7: e13-44. doi: 10.1016/j.jalz.2010.06.004 PMID: 21550318
4. Holtzman DM (2011) CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 32 Suppl 1: S4-9. doi: 10.1016/j.neurobiolaging.2011.09.003 PMID: 22078172
5. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, et al. (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59: 1267-1272. PMID: 12164722
6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292. doi: 10.1016/j.jalz.2011.03.003 PMID: 21514248
7. Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68: 666-669. PMID: 17325273
8. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM (2013) Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers. Clin Chem 59: 903-916. doi: 10.1373/clinchem.2013.202937 PMID: 23519967
9. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, w264. PMID: 19622511
10. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269. doi: 10.1016/j.jalz.2011.03.005 PMID: 21514250
11. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, et al. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39: 1159-1165. PMID: 2771064
12. Cooper JE (1995) On the publication of the Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition (DSM-IV). Br J Psychiatry 166: 4-8. PMID: 7894874
13. Becher B (2005) Failsafe N or file drawer number. In Rothstein H. R., Sutton A. J., & Bornstein M. (Eds.), Publication bias in meta-analysis: Prevention, assessment and adjustment. West Sussez, England: John Wiley & Sons. 14 p.
14. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods 1: 15.
15. Orwin R (1983) A fail-safe N for effect size in meta-analysis. Journal of Educational Statistics 8: 3.
16. Corwin R (1983) A fail-safe N for effect size in meta-analysis. Journal of Educational Statistics 8: 3.
17. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, et al. (2001) Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 172: 433-436. PMID: 11716567
18. Herukka SK, Hallikainen M, Soininen H, Pirttila T (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64: 1294-1297. PMID: 15824371
19. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234. PMID: 16488378
20. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, et al. (2009) Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44: 579-585. doi: 10.1016/j.exger.2009.06.003 PMID: 19539742
21. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, et al. (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23: 316-320. PMID: 17374949
22. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, et al. (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69: 631-639. PMID: 17698783
23. Song MS, Mook-Jung I, Lee HJ, Min JY, Park MH (2007) Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res 35: 301-306. PMID: 17593857
24. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80: 966-975. doi: 10.1136/jnnp.2008.167791 PMID: 19465413
25. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, et al. (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648. PMID: 7574461
26. Agarwal R, Tripathi CB (2011) Diagnostic Utility of CSF Tau and Abeta(42) in Dementia: A Meta-Analysis. Int J Alzheimers Dis 2011: 503293. doi: 10.4061/2011/503293 PMID: 22195288
27. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, et al. (1999) Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273: 5-8. PMID: 10505638
28. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K (2003) Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 179: 47-51. PMID: 12603251
29. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, et al. (2004) Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240-246. PMID: 15324367
30. Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, et al. (2014) Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. PLoS One 9: e100784. doi: 10.1371/journal.pone.0100784 PMID: 24959687
31. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 6: 419-430. doi: 10.2217/bmm.12.46 PMID: 22917144
32. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, et al. (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51: 189-195. PMID: 15539465
33. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, et al. (2012) Standardization of pre-analytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8: 65-73. doi: 10.1016/j.jalz.2011.07.004 PMID: 22047631
34. Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, et al. (2013) Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 80: 1124-1132. doi: 10.1212/WNL.0b013e318288690c PMID: 23446677
35. Dumurgier J, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, et al. (2013) Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiol Dis 54: 486-491. doi: 10.1016/j.nbd.2013.01.023 PMID: 23416172
36. Park SA, Kim JH, Kim HJ, Kim TE, Kim YJ, Lee DH, et al. (2013) Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Dementia and Neurocognitive Disorders 12: 1-8.
37. Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM (2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 53: 859-865. PMID: 17395712
38. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, et al. (2004) Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25: 273-281. PMID: 15123331
39. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, et al. (2004) Amyloid beta(1-42) and phosphorylated tau in CSF asmarkers for early-onset Alzheimer disease. Neurology 62: 1580-1584. PMID: 15136685
40. Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, et al. (2013) Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis 33: 117-131. doi: 10.3233/JAD-2012-121246 PMID: 22936010
41. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, et al. (2009) Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 4: e6294. doi: 10.1371/journal.pone.0006294 PMID: 19609443
42. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393. doi: 10.1001/jama.2009.1064 PMID: 19622817
43. Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, et al. (2009) Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol 62: 349-355. doi: 10.1159/000241881 PMID: 19786779
44. Herukka SK, Pennanen C, Soininen H, Pirttila T (2008) CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis 14: 51-57. PMID: 18525127
45. Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, et al. (2007) Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol 14: 168-173. PMID: 17250725
46. Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A (2005) The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. Int J Geriatr Psychiatry 20: 722-729. PMID: 16035118
47. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, et al. (2005) AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci 237: 83-88. PMID: 15990115
48. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, et al. (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9: 705-710. PMID: 14699432
49. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, et al. (2011) CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 77: 35-38. doi: 10.1212/WNL.0b013e318221ad47 PMID: 21700579
50. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, et al. (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 29: 812-818. PMID: 17239996